Bayesian Capital Management’s AbbVie ABBV Stock Holding History

Bayesian Capital Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$256K	Buy	+1,177	New	+$261K	0.31%	102
2025 Q4	–	Sell	-14,400	Closed	-$3.33M	–	110
2025 Q3	$3.33M	Buy	14,400 +4,900	+52%	+$998K	0.68%	22
2025 Q2	$1.76M	Sell	9,500 -4,700	-33%	-$873K	0.28%	102
2025 Q1	$2.98M	Buy	+14,200	New	+$2.76M	0.49%	48
2023 Q4	–	Sell	-3,500	Closed	-$522K	–	705
2023 Q3	$522K	Buy	+3,500	New	+$514K	0.06%	364
2021 Q4	–	Sell	-5,063	Closed	-$546K	–	363
2021 Q3	$546K	Sell	5,063 -41,237	-89%	-$4.71M	0.16%	175
2021 Q2	$5.21M	Buy	+46,300	New	+$5.21M	1.36%	12
2020 Q4	–	Sell	-83,700	Closed	-$7.33M	–	434
2020 Q3	$7.33M	Buy	83,700 +72,023	+617%	+$6.78M	1.79%	5
2020 Q2	$1.15M	Sell	11,677 -2,530	-18%	-$223K	0.25%	107
2020 Q1	$1.08M	Sell	14,207 -6,893	-33%	-$587K	0.23%	110
2019 Q4	$1.87M	Buy	+21,100	New	+$1.75M	0.32%	67
2019 Q3	–	Sell	-5,800	Closed	-$422K	–	504
2019 Q2	$422K	Buy	+5,800	New	+$456K	0.09%	296
2018 Q3	–	Sell	-38,500	Closed	-$3.57M	–	607
2018 Q2	$3.57M	Buy	38,500 +14,000	+57%	+$1.37M	0.8%	12
2018 Q1	$2.32M	Buy	24,500 +10,600	+76%	+$1.16M	0.59%	14
2017 Q4	$1.34M	Sell	13,900 -14,900	-52%	-$1.4M	0.27%	112
2017 Q3	$2.56M	Buy	28,800 +24,800	+620%	+$1.89M	0.61%	24
2017 Q2	$290K	Buy	+4,000	New	+$269K	0.11%	297
2016 Q1	–	Sell	-3,542	Closed	-$210K	–	344
2015 Q4	$210K	Buy	+3,542	New	+$204K	0.3%	165

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Bayesian Capital Management's ABBV Position: Q1 2026 in Review

Bayesian Capital Management opened a new position in AbbVie (ABBV) in Q1 2026: 1,177 shares worth $256K. The stake represents 0.31% of the portfolio and ranks #102 among its holdings. This is a return to the name: Bayesian Capital Management previously reported a position in ABBV as recently as Q3 2025.

Bayesian Capital Management first reported a position in ABBV in Q4 2015 and has held it in 18 quarters since. The position peaked at $7.33M in Q3 2020. 4,077 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Bayesian Capital Management held 1,177 shares of AbbVie worth $256K as of Q1 2026.
AbbVie was a new Bayesian Capital Management position in Q1 2026.
AbbVie made up 0.31% of Bayesian Capital Management's portfolio in Q1 2026, its #102 holding.
Bayesian Capital Management first reported a position in AbbVie in Q4 2015 and has held it in 18 quarters since.
Bayesian Capital Management's AbbVie position peaked at $7.33M in Q3 2020.
4,077 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Bayesian Capital Management's 13F filing for Q1 2026, filed 15 May 2026.